Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 11;13:72. doi: 10.1186/s13578-023-01015-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 4 — CLDN1 is a key mediator to oxaliplatin resistance in CRC cell lines (A) CLDN1 membrane expression in oxaliplatin-resistant cell lines and their parental cell lines. Top: Immunofluorescence images of CLDN1 membrane expression in SW620-ROX cells (oxaliplatin resistant) and in SW620 cells (parental line). (B) Effect of CLDN1 silencing (shCLDN1) on oxaliplatin IC50 in the two oxaliplatin-resistant cell lines incubated with oxaliplatin compared with the shLUC controls. (C) Five GSEA hallmarks deregulated after oxaliplatin treatment with significantly enriched genes in SW620_ROX–shCLDN1 and -shLUC cells. Dot plots indicate the gene ratios (number of core genes over the total number of genes in the set). Dots are colored in function of the adjusted p-value and their size in the gene set. (D) Enrichment plots for the apoptosis hallmark. The location of the gene set members is indicated by vertical black lines and showed a significant positive enrichment (left) in SW620_ROX–shCLDN1 cell samples compared with SW620_ROX-shLUC samples (E) FACS profiles of annexin V-APC/7-AAD staining in the two oxaliplatin-resistant cell lines in which CLDN1 was silenced (-shCLDN1) or not (-shLUC) and incubated or not with oxaliplatin (5µM for 24 h). Apoptosis was quantified in at least three experiments (Student’s t-test)